FeesSafety
Pluang+

Tilray's revenue rose due to acquisition, but cannabis sales fell 13% and it returned to operating loss.

Market News
21 Nov 2026, 23:51 WIB
The Motley Fool
View Source
Bearish
Tilray's revenue rose due to acquisition, but cannabis sales fell 13% and it returned to operating loss.

Tilray Brands reported a 23% revenue increase in its latest quarter, mainly driven by acquiring BrewDog assets, while its core cannabis sales dropped 13%. The company swung back to an operating loss of $24.1 million and faces ongoing regulatory challenges in the U.S., Canada, and other markets. With uncertain U.S. federal legalization and tough international regulations, Tilray's future growth remains doubtful, making its stock a risky investment despite record low prices.

Tilray Brands is trading at a low USD 1.89 on Pluang as of Nov 22, 2026 05:02 WIB, down 8.70% in one day, highlighting its struggle despite recent revenue gains. Its market cap stands at $279.32 million, reflecting investor caution amid ongoing regulatory challenges. The typical hold time of 33 days suggests relatively short-term interest compared to more stable health sector stocks.

More News (TLRY)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App